Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
Community
/
United States
/
Pharmaceuticals & Biotech
Create a narrative
Xeris Biopharma Holdings Community
NasdaqGS:XERS Community
1
Narratives
written by author
0
Comments
on narratives written by author
9
Fair Values set
on narratives written by author
Community Investing Ideas
Xeris Biopharma Holdings
Popular
Undervalued
Overvalued
Xeris Biopharma Holdings
AN
AnalystConsensusTarget
Consensus Narrative from 6 Analysts
Expanding Patient Demand And Pipeline Launches Will Reshape Healthcare Markets
Key Takeaways Strong demand for key therapies and strategic investments in commercialization and partnerships are expected to drive sustained revenue growth and operational leverage. Expansion into underserved markets and focus on innovation position the company to capture new revenue streams and support long-term profit margin improvement.
View narrative
US$9.00
FV
13.9% undervalued
intrinsic discount
21.47%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
6
users have followed this narrative
Updated
narrative
Your Valuation for
XERS
XERS
Xeris Biopharma Holdings
Your Fair Value
US$
Current Price
US$7.75
20.0% overvalued
intrinsic discount
Growth estimate over
Annual revenue growth rate
5 Years
time period
%/yr
Decrease
Increase
Past
Future
-137m
545m
2015
2018
2021
2024
2025
2027
2030
Revenue US$544.7m
Earnings US$80.2m
Advanced
Set Fair Value